📣 Help Shape the Future of UKRI's Gateway to Research (GtR)

We're improving UKRI's Gateway to Research and are seeking your input! If you would be interested in being interviewed about the improvements we're making and to have your say about how we can make GtR more user-friendly, impactful, and effective for the Research and Innovation community, please email gateway@ukri.org.

Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial. (2020)

First Author: Folegatti PM

Attributed to: Rapid development of manufacturing processes for future production of adenovirus-vectored COVID19 vaccine at million-dose scale funded by COVID

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1016/s0140-6736(20)31604-4

PubMed Identifier: 32702298

Publication URI: http://europepmc.org/abstract/MED/32702298

Type: Journal Article/Review

Volume: 396

Parent Publication: Lancet (London, England)

Issue: 10249

ISSN: 0140-6736